http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

米氮平血药浓度HPLC-MS检测法及其生物利用度

李荣珊, 丁黎*, 简龙海, 肖红   

  1. 1.中国药科大学药物分析教研室, 江苏 南京 210009;
    2.南京市脑科医院国家药品临床药理基地, 江苏 南京 210029
  • 收稿日期:2004-04-06 修回日期:2004-08-10 出版日期:2004-09-15 发布日期:2004-09-15
  • 通讯作者: 丁黎*

Determination of Mirtazapine in Human Plasma by HPLC-MS and Bioavailability of Newly Developed Mirtazapine Tablets in Healthy Volunteers

LI Rong-shan, DING Li*, JIAN Long-hai, XIAO Hong   

  1. 1.Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China;
    2.National Drug Clinical Research Base, Nanjing Brain Hospital, Nanjing 210029, China
  • Received:2004-04-06 Revised:2004-08-10 Online:2004-09-15 Published:2004-09-15
  • Contact: DING Li*

摘要: 目的 建立人血浆中米氮平的HPLC-ESI-MS测定法, 以测定志愿者口服米氮平片剂(30mg/)后的血药浓度,并对受试制剂和参比制剂的生物等效性进行评价. 方法 20名健康志愿者交叉口服供试片和参比片, 剂量均为30mg. 采用HPLC-ESI-MS法测定人血浆中米氮平浓度.计算主要药动学参数及相对生物利用度. 结果 0.3-200ng·mL-1范围内米氮平与内标峰面积比值与浓度线性关系良好,最低定量限为0.1ng·mL-1. 受试制剂及参比制剂的生物半衰期分别为(24.7±4.1)h(23.6±4.3)h, 达峰时间分别为(1.6±0.8)(1.5±0.8)h, 峰浓度分别为(95.9±29.8)(91.9±26.7)ng·mL-1. AUC0-120计算的受试制剂的相对生物利用度为(100.0±10.8)%. 结论 本实验建立的人血浆中米氮平的HPLC-MS分析方法灵敏、准确、简便.统计学结果表明两种米氮平制剂生物等效.

关键词: 米氮平, 米氮平, 米氮平, 药物动力学, 药物动力学, 药物动力学, 生物利用度, 生物利用度, 生物利用度, 液质联用, 液质联用, 液质联用

Abstract: Aim To establish a sensitive and specific liquid chromatography-mass spectrometry method for determination of mirtazapine in human plasma and evaluation of its relative bioavailability. Methods After being alkalized by 25% ammonia, mirtazapine in the plasma was extracted with n-hexane. Desloratadine was used as internal standard (IS). Solu-tes were separated on a C18 column with a mobile phase of methanol-ammonium acetate buffer (pH 3.5) (75:25). The flow rate of the mobile phase was 1 mL·min-1. Detection was performed on an electrospray ionization (ESI) mass spectrometer and operated in selected ion monitoring (SIM) and positive-ionization mode using target ionsat m/z 266.2 for mirtazapine and m/z 311.2 for the IS. The fragmentor voltage was 90 V. A randomized cross-over study was performed in 20 healthy volunteers. In the two study periods, twenty healthy Chinese male subjects received a single oral dose of mirtazapine 30 mg. Results The calibration curve was linear over the range of 0.3-200 ng·mL-1. The limit of quantitation was 0.1 ng·mL-1. The parameters for mirtazapine test tablet and reference tablet were as follows: T1/2(24.7±4.1) and (23.6±4.3) h, Tmax(1.6±0.8) and (1.5±0.8) h, Cmax(95.9±29.8) and (91.9±26.7) ng·mL-1, respectively. Conclusion The established HPLC-MS method is rapid, sensitive and specific for the determination of mirtazapine in human plasma. The relative bioavailability was 100.0%±10.8%.

Key words: mirtazapine, mirtazapine, pharmacokinetics, pharmacokinetics, bioavailability, bioavailability, HPLC-MS, HPLC-MS

中图分类号: 

Supporting: *Corresponding author. Tel.: 86-25-83271289